The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: A prospective study

Leukemia Research

Volumn 33, Issue 8, 2009, Pages 1039-1046

  Truong, Francoise ^a   Smith, Brian R ^b   Stachurski, Dariusz ^c   Cerny, Jan ^a   Medeiros, L Jeffery ^d   Woda, Bruce A ^a   Wang, Sa A ^d  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cytopenia; Flow cytometry; Idiopathic cytopenia of uncertain significance; Melodysplastic syndrome

Indexed keywords

ADULT; AGED; ARTICLE; BONE MARROW; BONE MARROW CELL; CELL MATURATION; CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; IDIOPATHIC DISEASE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 67349158281     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.01.012     Document Type: Article

References (37)

1. Adams P.F., Hendershot G.E., and Marano M.A. Current estimates from the National Health Interview Survey, 1996. Vital Health Stat 10 (1999) 1-203
2. DeMaeyer E., and Adiels-Tegman M. The prevalence of anaemia in the world. World Health Stat Q 38 (1985) 302-316
3. Dubois R.W., Goodnough L.T., Ershler W.B., Van Winkle L., and Nissenson A.R. Identification, diagnosis, and management of anemia in adult ambulatory patients treated by primary care physicians: evidence-based and consensus recommendations. Curr Med Res Opin 22 (2006) 385-395
4. Goldstein K.H., and Abramson N. Efficient diagnosis of thrombocytopenia. Am Fam Physician 53 (1996) 915-920
5. Kuijpers T.W., Weening R.S., and Roos D. Clinical and laboratory work-up of patients with neutrophil shortage or dysfunction. J Immunol Methods 232 (1999) 211-229
6. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
7. WHO classification of tumours of haematopoietic and lymphoid tissues. In: Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., and Vardiman J.W. (Eds). World Health Organization classification of tumours. 4th ed. (2008), IARC Press, Lyon
8. Gupta R., Soupir C.P., Johari V., and Hasserjian R.P. Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. Br J Haematol 139 (2007) 265-268
9. Kuroda J., Kimura S., Kobayashi Y., Wada K., Uoshima N., and Yoshikawa T. Unusual myelodysplastic syndrome with the initial presentation mimicking idiopathic thrombocytopenic purpura. Acta Haematol 108 (2002) 139-143
10. Vardiman J.W. Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program) (2006) 199-204
11. Schmitt-Graeff A., Mattern D., Kohler H., Hezel J., and Lubbert M. Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis. Pathologe 21 (2000) 1-15
12. Sole F., Espinet B., Sanz G.F., Cervera J., Calasanz M.J., Luno E., et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. Br J Haematol 108 (2000) 346-356
13. Young N.S., Calado R.T., and Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 108 (2006) 2509-2519
14. Konoplev S., Medeiros L.J., Lennon P.A., Prajapati S., Kanungo A., and Lin P. Therapy may unmask hypoplastic myelodysplastic syndrome that mimics aplastic anemia. Cancer 110 (2007) 1520-1526
15. Della Porta M.G., Malcovati L., Invernizzi R., Travaglino E., Pascutto C., Maffioli M., et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia 20 (2006) 549-555
16. Kussick S.J., Fromm J.R., Rossini A., Li Y., Chang A., Norwood T.H., et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol 124 (2005) 170-181
17. Malcovati L., Della Porta M.G., Lunghi M., Pascutto C., Vanelli L., Travaglino E., et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia 19 (2005) 776-783
18. Ogata K., Kishikawa Y., Satoh C., Tamura H., Dan K., and Hayashi A. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 108 (2006) 1037-1044
19. Stetler-Stevenson M., Arthur D.C., Jabbour N., Xie X.Y., Molldrem J., Barrett A.J., et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 98 (2001) 979-987
20. Wells D.A., Benesch M., Loken M.R., Vallejo C., Myerson D., Leisenring W.M., et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 102 (2003) 394-403
21. Scott B.L., Wells D.A., Loken M.R., Myerson D., Leisenring W.M., and Deeg H.J. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood 112 (2008) 2681-2686
22. Stachurski D., Smith B.R., Pozdnyakova O., Andersen M., Xiao Z., Raza A., et al. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls. Leuk Res 32 (2008) 215-224
23. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 36 (2000) 69-86
24. Mitelman F. An International System for Human Cytogenetic Nomenclature (ISCN); 1995.
25. Beutler E., and Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration?. Blood 107 (2006) 1747-1750
26. Beloosesky Y., Cohen A.M., Grosman B., and Grinblat J. Prevalence and survival of myelodysplastic syndrome of the refractory anemia type in hospitalized cognitively different geriatric patients. Gerontology 46 (2000) 323-327
27. Tuzuner N., Cox C., Rowe J.M., Watrous D., and Bennett J.M. Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol 91 (1995) 612-617
28. Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon
29. Birrer A., Jusufi F., Bernimoulin M., Tichelli A., Gratwohl A., Nissen-Druey C., et al. Hematopoietic progenitor cell colony growth differentiates chronic myelomonocytic leukemia from reactive monocytosis. Eur J Haematol 81 (2008) 267-272
30. Xu Y., McKenna R.W., Karandikar N.J., Pildain A.J., and Kroft S.H. Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Am J Clin Pathol 124 (2005) 799-806
31. Matsui W.H., Brodsky R.A., Smith B.D., Borowitz M.J., and Jones R.J. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia 20 (2006) 458-462
32. Maftoun-Banankhah S., Maleki A., Karandikar N.J., Arbini A.A., Fuda F.S., Wang H.Y., et al. Multiparameter flow cytometric analysis reveals low percentage of bone marrow hematogones in myelodysplastic syndromes. Am J Clin Pathol 129 (2008) 300-308
33. Matarraz S., Lopez A., Barrena S., Fernandez C., Jensen E., Flores J., et al. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia 22 (2008) 1175-1183
34. Satoh C., Dan K., Yamashita T., Jo R., Tamura H., and Ogata K. Flow cytometric parameters with little interexaminer variability for diagnosing low-grade myelodysplastic syndromes. Leuk Res 32 (2008) 699-707
35. van de Loosdrecht A.A., Westers T.M., Westra A.H., Drager A.M., van der Velden V.H., and Ossenkoppele G.J. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 111 (2008) 1067-1077
36. Valent P., Horny H.P., Bennett J.M., Fonatsch C., Germing U., Greenberg P., et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 31 (2007) 727-736
37. Wimazal F., Fonatsch C., Thalhammer R., Schwarzinger I., Mullauer L., Sperr W.R., et al. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res 31 (2007) 1461-1468